shutterstock_1505189714_estherpoon
estherpoon / Shutterstock.com
1 December 2022FeaturesPharmaRebecca Anderson-Smith

Exhaustion and parallel trade: what’s next for pharma TMs?

Ever since the UK announced its intended departure from the European Union (EU), there has been much speculation about whether and how the UK would amend its trademark exhaustion and parallel trade regime. Following the recent UK government consultation, the position has become clearer, although the government has not ruled out the possibility of making further changes in the future.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
25 September 2026   Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.
Pharma
24 September 2026   An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.
Pharma
22 September 2026   After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.